GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera AG (XTER:B8FK) » Definitions » Cyclically Adjusted Price-to-FCF

Biofrontera AG (XTER:B8FK) Cyclically Adjusted Price-to-FCF : (As of May. 26, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Biofrontera AG Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Biofrontera AG Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Biofrontera AG's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofrontera AG Cyclically Adjusted Price-to-FCF Chart

Biofrontera AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Biofrontera AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biofrontera AG's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biofrontera AG's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Biofrontera AG's Cyclically Adjusted Price-to-FCF falls into.



Biofrontera AG Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Biofrontera AG's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Biofrontera AG's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/123.7729*123.7729
=0.000

Current CPI (Dec. 2023) = 123.7729.

Biofrontera AG Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -1.803 99.543 -2.242
201406 -1.491 99.543 -1.854
201409 -1.600 99.823 -1.984
201412 -1.210 99.543 -1.505
201503 -1.356 99.717 -1.683
201506 -4.096 100.417 -5.049
201509 -1.156 100.417 -1.425
201512 -1.152 99.717 -1.430
201603 0.056 100.017 0.069
201606 -1.677 100.717 -2.061
201609 -2.731 101.017 -3.346
201612 -2.470 101.217 -3.020
201703 -2.156 101.417 -2.631
201706 -2.142 102.117 -2.596
201709 -2.078 102.717 -2.504
201712 -0.497 102.617 -0.599
201803 0.000 102.917 0.000
201806 0.000 104.017 0.000
201809 0.000 104.718 0.000
201812 0.000 104.217 0.000
201903 0.000 104.217 0.000
201906 0.000 105.718 0.000
201909 0.000 106.018 0.000
201912 0.000 105.818 0.000
202003 0.000 105.718 0.000
202006 0.000 106.618 0.000
202009 0.000 105.818 0.000
202012 0.000 105.518 0.000
202103 0.000 107.518 0.000
202106 0.000 108.486 0.000
202109 0.000 109.435 0.000
202112 0.000 110.384 0.000
202203 0.000 113.968 0.000
202206 0.000 115.760 0.000
202209 0.000 118.818 0.000
202212 0.000 119.345 0.000
202303 0.000 122.402 0.000
202306 0.000 123.140 0.000
202309 0.000 124.195 0.000
202312 0.000 123.773 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biofrontera AG  (XTER:B8FK) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Biofrontera AG Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Biofrontera AG's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Biofrontera AG (XTER:B8FK) Business Description

Industry
Traded in Other Exchanges
Address
Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.

Biofrontera AG (XTER:B8FK) Headlines

No Headlines